AMEX
1.62USD
+0.02 (+1.25%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
73.8M
P/E
—
EPS
—
Beta
-0.73
52W range
1.15-2.57
Day range
1.56–1.63
Open
1.58
Prev close
1.60
Volume
399.8K
Avg volume
688.9K
Dividend
0.00
IPO
2024-08-01
https://www.newsfilecorp.com/release/309887/OS-Therapies-Reports-Second-Quarter-2026-Financials-and-Provides-Business-and-Regulatory-Updates · 8/17/2026+0.30
https://www.newsfilecorp.com/release/303383/OS-Therapies-Provides-U.S.-Regulatory-Update · 6/30/2026+0.80
https://www.newsfilecorp.com/release/302971/OS-Animal-Health-Announces-PeerReviewed-Publication-of-Clinical-Trial-Data-for-OSTHER2-Plus-Palliative-Radiation-as-Frontline-Treatment-in-Canine-Osteosarcoma · 6/26/2026+0.80
https://www.newsfilecorp.com/release/298851/OS-Therapies-to-Attend-Upcoming-Medical-Financial-and-Industry-Conferences · 5/26/2026+0.60
https://www.newsfilecorp.com/release/297679/OS-Therapies-to-Announce-First-Quarter-2026-Financials-on-Monday-May-18-2026 · 5/15/2026
https://www.businesswire.com/news/home/20260411928408/en/OS-Therapies-Investor-News-Rosen-Law-Firm-Encourages-OS-Therapies-Incorporated-Investors-to-Inquire-About-Securities-Class-Action-Investigation-%E2%80%93-OSTX/ · 4/11/2026-0.80
https://www.newsfilecorp.com/release/277041/OS-Therapies-Announces-FDA-PDUFA-Waiver-EMA-Grants-Union-Marketing-Authorisation-Eligibility · 12/5/2025+1.00
https://www.newsfilecorp.com/release/268502/OS-Therapies-Provides-OSTHER2-UK-MHRA-and-US-FDA-Osteosarcoma-Regulatory-Update · 9/30/2025+0.60
https://www.newsfilecorp.com/release/267123/OS-Therapies-to-Participate-in-Spotlight-Panel-at-BioFuture-2025-October-13-1100am-EDT · 9/19/2025+0.80
https://www.newsfilecorp.com/release/263891/OS-Therapies-Terminates-Equity-Line-of-Credit · 8/26/2025+0.60
https://www.fool.com/data-news/2025/08/19/os-therapies-posts-wider-loss-in-q2/ · 8/19/2025-0.20
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
